NR3C2 and Hyperkalemia: RASi and MR antagonists might be legitimately withheld due to well-justified fears of hyperkalemia in patients with significant risk factors or in patients who prioritize avoidance of hyperkalemia (or other factors such as tablet burden) over any potential prognostic benefit.